Compare GPI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPI | LIVN |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 1997 | 2015 |
| Metric | GPI | LIVN |
|---|---|---|
| Price | $300.94 | $59.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $460.86 | $72.43 |
| AVG Volume (30 Days) | 139.2K | ★ 881.7K |
| Earning Date | 04-30-2026 | 06-01-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 25.24 | N/A |
| Revenue | ★ $11,123,721,000.00 | N/A |
| Revenue This Year | $3.68 | $9.15 |
| Revenue Next Year | $3.19 | $6.67 |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | ★ 2.17 | N/A |
| 52 Week Low | $306.96 | $32.48 |
| 52 Week High | $488.39 | $71.58 |
| Indicator | GPI | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 24.06 | 31.09 |
| Support Level | N/A | $49.51 |
| Resistance Level | $409.75 | $65.25 |
| Average True Range (ATR) | 10.77 | 2.31 |
| MACD | -0.46 | -1.11 |
| Stochastic Oscillator | 0.88 | 0.33 |
Group 1 owns and operates 32 collision centers and 254 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 109 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.